Brief: Briacell Highlights Outstanding Topline Survival And Clinical Benefit Data In Advanced Metastatic Breast Cancer At The 2023 Sabcs
06/12/2023 15:19
Dec 6 (Reuters) - Briacell Therapeutics Corp BCT.TO :
* BRIACELL HIGHLIGHTS OUTSTANDING TOPLINE SURVIVAL AND
CLINICAL
BENEFIT DATA IN ADVANCED METASTATIC BREAST CANCER AT THE 2023
SABCS
* BRIACELL THERAPEUTICS CORP - ALL PATIENTS WERE ABLE TO
RECEIVE
THERAPY WITH NO TOXICITY RELATED DISCONTINUATIONS
* BRIACELL THERAPEUTICS CORP - MEDIAN OVERALL SURVIVAL OF
13.4
MONTHS IN PATIENTS TREATED WITH BRIA-IMT™ COMBINATION REGIMEN
* BRIACELL THERAPEUTICS CORP - 32 OUT OF 42 PATIENTS TREATED
SINCE
2022 REMAIN ALIVE SUGGESTING CONSISTENTLY STRONG SURVIVAL
BENEFIT
Source text for Eikon: ID:nGNX7RX7St
Further company coverage: BCT.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study